Translational Hematology

Prof.ssa Marta Coscia (Principal Investigator)

Activities

The research activity of the laboratory of Translational Hematology is focused on:

The evaluation of immune dysfunctions occurring in patients with lymphoproliferative diseases, with a special interest in patients with chronic lymphocytic leukemia (CLL)
The impact of conventional and novel targeted therapies on the immune system of patients with lymphoproliferative diseases and CLL
The study of intrinsic, microenvironment-related or immune-mediated mechanisms favouring tumor progression and inducing resistance to apoptosis and to drug-induced cell death in CLL cells.
Development of novel strategies of adoptive immunotherapy, with the aim of improving anti-tumor efficacy and reducing side effects in lymphoproliferative diseases

Group:

Research Funding from Janssen Research & Development, LLC: "Immunomodulatory effects of single-agent ibrutinib treatment in chronic lymphocytic leukemia patients", Ruolo: Principal Investigator (2016 – presente).
Research Funding from Karyopharm Therapeutics Inc., a Delaware corporation: "In vitro evaluation of the activity of Selinexor (KPT-330) in combination with antineoplastic agents against chronic lymphocytic leukemia primary cells", Ruolo: Principal Investigator (2014 – presente).
Sponsored Phase I/III clinical trials investigating the efficacy of innovative treatments in chronic lymphocytic leukemia. Role: Principal Investigator (2014 - presente).
AIRC19653 Fellowship: “Exploring the regulation of HIF-1α and its potential for therapeutic intervention in chronic lymphocytic leukemia”.
AIRC16343 Fellowship: “Understanding the CXCL12/CXCR4 axis and mevalonate pathway cross-talk to overcome fludarabine resistance in CLL”.
Active participation to the research and clinical projects of ERIC, GIMEMA gruppo linfoproliferative croniche.